Halo Pharmaceutical

Halo Pharma is a contract development and manufacturing organization (CDMO) that provides scientific and development expertise, as well as a wide spectrum of manufacturing services, from its locations in Whippany, New Jersey, USA, and Montreal, Quebec, Canada, to its international client base. Halo Pharma offers fully integrated capabilities across a variety of dosage forms, including solid, semi-solid, and oral liquid, and is expanding to include sterile vial, prefilled syringe, and cartridge formats.

SK Capital made a controlling strategic growth investment in Halo Pharmaceutical in January 2015.

In September 2018,  Halo Pharmaceutical was sold to Cambrex Corporation (NYSE: CBM).

In 2023, SK Capital, through Noramco, reacquired Halo Pharmaceuticals from Cambrex Corporation (NYSE: CBM).

Today, Halo operates as a standalone CDMO under SK’s ownership.